宫颈癌术后输注细胞因子诱导的杀伤细胞治疗前后外周血免疫指标的变化

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (976 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the changes of immune parameters of patients with different cervical cancer treated with cytokine-induced killer(CIK)cells after radical hysterectomy in order to provide data for clinical evaluation.Methods 50 ml peripheral blood was collected the day before CIK cell therapy and after a course of treatment from ninety-eight radical hysterectomy patients(56 cases of squamous carcinoma, 25 cases of adenocarcinoma,and 17 cases of adenosquamous carcinoma) treated in the Department of Gynaecology and Obstetrics and Department of Oncology between January 2014 and September 2016.According to the process of CIK cell therapy, the serum was separated, and the proportion of CD3⁺、CD4⁺、CD8⁺、CD4/CD8、and NK cells in the serum was analyzed using flow cytometry (FCM).Results 1.The proportion of CD3⁺ and NK cells in the 98 patients was increased after CIK cell therapy.The proportion of CD4⁺ and CD4/CD8 rose only in patients of squamous carcinoma and adenocarcinoma.The proportion of CD8⁺ did not change significantly.2.The result of CD3⁺ and NK cells suggested that after treatment the immune parameters in patients of adenocarcinoma were significantly higher than those in patients of squamous carcinoma and adenosquamous carcinoma (P<0.05).After treatment, CD3⁺ and NK cells increased from 60.71±5.84 to 67.27±3.04 and from 8.92±3.64 to 12.93±6.25 respectively in patients of squamous carcinoma, from 59.91±2.49 to 68.32±8.24 and from 9.04±5.31 to 17.87±6.46 respectively in patients of adenocarcinoma,and finally from 59.01±5.90 to 65.23±7.07 and from 59±3.97 to 15.07±2.71 respectively in patients of adenosquamous carcinoma.Conclusions CIK cell therapy can markedly enhance the immunity of patients after radical hysterectomy. It’s of great significance for improving the quality of survival.

Key words： cytokine induced killer cervical cancer immune parameters

Received: 11 August 2016

ZTFLH:

R737.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Hua
	LIU Zhengli
	and XU Xia

Cite this article:

ZHAO Hua,LIU Zhengli,and XU Xia. Changes of immune parameters in cervical cancer patients after CIK cell therapy[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2017, 28(4): 358-360.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2017/V28/I4/358

[1]	雷张涛,叶红.宫颈癌肿瘤干细胞的研究进展[J]. 医学综述, 2012, 7(8): 1156-1158.
[2]	Antill Y C,Dowty J G,Win A K, et al. Lynch Syndrome and Cervical Cancer[J]. Int J Cancer, 2015, 137(11): 2757-2761.
[3]	Schmeel L C,Schmeel F C,Coch C, et al. Cytokine-induced Killer (cik) Cells in Cancer Immunotherapy: Report of the International Registry on Cik Cells (ircc)[J]. J Cancer Res and Clin Oncol, 2015, 141(5): 839-849.
[4]	Dasari S,Wudayagiri R,Valluru L. Cervical Cancer: Biomarkers for Diagnosis and Treatment[J]. Clin Chim Acta, 2015, 445(9): 7-11.
[5]	罗光华,马鸣,郭莉莉,等. CIK细胞治疗对肿瘤患者外周血免疫细胞亚型的影响[J]. 中国肿瘤生物治疗杂志, 2013, 12(4): 475-477.
[6]	吕晓霞,陈帼玲,王学群,等. 自体CIK细胞治疗21例中晚期恶性实体瘤的肿瘤标志物变化观察[J]. 中华细胞与干细胞杂志, 2014, 7(3): 165-174.
[7]	林兰,刘继斌. 中晚期消化系恶性肿瘤CIK细胞治疗前后免疫功能变化的价值[J]. 肿瘤基础与临床, 2010, 12(5): 399-401.
[8]	赵华,贾咏梅. DC-CIK免疫治疗联合常规化疗对非小细胞肺癌患者血清学及外周血免疫功能指标的影响[J]. 海南医学院学报, 2015, 6(7): 967-970.
[9]	苏小岩,胡艳,张文涛,等. DC-CIK细胞免疫治疗联合放疗治疗中晚期宫颈癌的疗效观察[J]. 长江大学学报(自科版), 2014, 4(33): 4, 77-79.
[10]	田志刚. 基于NK细胞的肿瘤免疫治疗研究进展[J]. 中国肿瘤生物治疗杂志,2009,1:2-5.
[11]	周怡,蒋敬庭. 细胞因子在CIK细胞抗肿瘤治疗中的作用[J]. 临床检验杂志,2014,32(2):115-117.
[12]	邢宏,韩方正,汪莉萍. 细胞因子诱导的杀伤细胞CIK的基础与临床研究新进展[J].中国免疫学杂志,2011,27(1):88-92.
[13]	张丽鹏,李新伟,黄宽军,等. DC-CIK细胞免疫治疗晚期结直肠癌患者的远期疗效及影响因素分析[J].现代生物医学进展,2016,22(16):4348-4351.
[14]	李晓英,鲍杨漪,江蓓蕾,等. 不同类型肿瘤患者自体CIK 细胞治疗对机体免疫状态及临床症状改善的影响[J].安徽医科大学学报,2012,47(4):434-437.
[15]	Akyol M,Ulger E,Alacacioglu A,et al.Quality of life in colorectal cancer patients:an Izmir Oncology Group (IZOG)study[J]. J Buon,2015,20(4):1015-1022.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(7): 629-632.